Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin
NCT ID: NCT01795937
Last Updated: 2015-08-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
51 participants
INTERVENTIONAL
2013-02-28
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin
NCT01635946
A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.
NCT01138072
Drug Interaction Statin
NCT02089061
Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
NCT05154123
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
NCT00235950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Faldaprevir + Itraconazole
Interaction of Faldaprevir and Itraconazole
Itraconazole
twice daily
Faldaprevir
once daily
Part 2:Faldaprevir+Rosuvastatin+Atorvast
Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
Atorvastatin
single dose
Faldaprevir
once daily
Rosuvastatin
single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Itraconazole
twice daily
Atorvastatin
single dose
Faldaprevir
once daily
Rosuvastatin
single dose
Faldaprevir
once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1220.61.1 Boehringer Ingelheim Investigational Site
Ingelheim, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-005518-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
1220.61
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.